Spine metastasis in patients with prostate cancer: Survival prognosis assessment

Amelot, Aymeric; Terrier, Louis-Marie; Nail, Louis-Romée Le; Cristini, Joseph; Cook, Ann-Rose; Buffenoir, K.; Pascal‐Moussellard, Hugues; Carpentier, Alexandre; Dubory, Arnaud; Mathon, Bertrand

doi:10.1002/pros.24084

Cited by 7 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, bone metastasis is a significant milestone in the progression of prostate cancer and represents a systemic disease that greatly affects patient prognosis. Once bone metastasis occurs, prostate cancer patients may experience symptoms, such as bone pain, pathological fractures, and spinal cord compression, ultimately leading to a reduced quality of life and shortened lifespan [ 41 ]. Our findings indicated that PTHrP expression in tissues was significantly higher in phases M1b and M1c compared to phases M0 and M1a, implying that PTHrP may play a role in the bone metastasis process in clinical prostate cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Parathyroid hormone-related protein as a potential prostate cancer biomarker: Promoting prostate cancer progression through upregulation of c-Met expression

Zhao,

Fu,

Feng

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

Parathyroid hormone-related protein (PTHrP) plays a significant role in various tumor types, including prostate cancer. However, its specific role and underlying mechanisms in prostate cancer remain unclear. This study investigates the role of PTHrP and its interaction with the mesenchymal-epithelial transition factor (c-Met) in prostate cancer. PTHrP was overexpressed and knocked down in prostate cancer cell lines to determine its effect on cell functions. Xenograft tumor models were employed to assess the impact of PTHrP overexpression on tumor growth. To delve into the interaction between PTHrP and c-Met, rescue experiments were conducted. Clinical data and tissue samples from prostate cancer patients were gathered and analyzed for PTHrP and c-Met expression. PTHrP overexpression in prostate cancer cells upregulates c-Met expression and augments cell functions. In contrast, PTHrP knockdown diminishes c-Met expression and inhibites cell functions. In vivo experiments further demonstrated that PTHrP overexpression promoted tumor growth in xenograft models. Moreover, modulating c-Met expression in rescue experiments led to concurrent alterations in prostate cancer cell functions. Immunohistochemical analysis of clinical samples displayed a significant positive correlation between PTHrP and c-Met expression. Additionally, PTHrP expression correlated with clinical parameters like prostate-specific antigen (PSA) levels, tumor stage, lymph node involvement, distant metastasis, and Gleason score. PTHrP plays a crucial role in prostate cancer progression by upregulating c-Met expression. These insights point to PTHrP as a promising potential biomarker for prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Parathyroid hormone-related protein as a potential prostate cancer biomarker: Promoting prostate cancer progression through upregulation of c-Met expression

Zhao,

Fu,

Feng

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

show abstract

“…Regarding the effect of spine surgery for SSM on survival, several studies report that spine surgery provides the opportunity for patients to receive adjuvant therapy and thus may lead to improved survival [ 9 , 13 , 31 ]. However, these studies were also retrospective and included patients who received chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Survival Rate after Palliative Surgery Alone for Symptomatic Spinal Metastases: A Prospective Cohort Study

Kakutani

Sakai

Zhang

et al. 2022

JCM

View full text Add to dashboard Cite

The effect of spine surgery for symptomatic spinal metastases (SSM) on patient prognosis remains unclear. This study aimed to reveal the prognosis of patients with SSM after spine surgery. One hundred twenty-two patients with SSM were enrolled in this prospective cohort study. The patients who received chemotherapy after enrollment were excluded. The decision of surgery depended on patient’s willingness; the final cohort comprised 31 and 24 patients in the surgery and non-surgery groups, respectively. The patients were evaluated by their performance status (PS), activities of daily living (ADL) and ambulatory status. Survival was evaluated by the Kaplan–Meier method. The PS, ADL and ambulation were significantly improved in the surgery group compared to non-surgery group. The median survival was significantly longer in the surgery group (5.17 months, 95% confidence interval (CI) 3.27 to 7.07) than in the non-surgery group (2.23 months, 95% CI 2.03 to 2.43; p = 0.003). Furthermore, the patients with a better PS, ADL and ambulatory status had a significantly longer survival. Surgery improved the PS, ADL, ambulation and survival of patients with SSM. In the management of SSM, spine surgery is not only palliative but may also prolong survival.

show abstract

“…Prostate cancer will commonly metastasize to bone and OS in patients with spine metastases is roughly 2.5 years. 53 According to SEER, 7% patients diagnosed with prostate cancer have distant metastases at presentation, with 30.6% 5-year relative survival. 14 Androgen receptor antagonists including flutamide, bicalutamide and abiraterone are commonly used as first-line androgen deprivation agents resulting in improvement in patient outcomes; as reported by STAMPEDE trial median OS was not reached with addition of zoledronic acid, 81 months with addition of docetaxel, 76 months with addition of both, and 71 months with standard of care (Table 1).…”

Section: Prostate Cancermentioning

confidence: 99%

“…Prostate cancer will commonly metastasize to bone and OS in patients with spine metastases is roughly 2.5 years [ 53 ]. According to SEER, 7% patients diagnosed with prostate cancer have distant metastases at presentation, with 30.6% 5-year relative survival [ 14 ].…”

Section: Prostate Cancermentioning

confidence: 99%

Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Fomchenko

Bayley²,

Alvarez‐Breckenridge³

et al. 2022

Neurospine

View full text Add to dashboard Cite

Metastatic involvement of the spine is a common complication of systemic cancer progression. Surgery and external beam radiotherapy are palliative treatment modalities aiming to preserve neurological function, control pain and maintain functional status. More recently, with development of image guidance and stereotactic delivery of high doses of conformal radiation, local tumor control has improved; however recurrent or radiation refractory disease remains a significant clinical problem with limited treatment options. This manuscript represents a narrative overview of novel targeted molecular therapies, chemotherapies, and immunotherapy treatments for patients with breast, lung, melanoma, renal cell, prostate, and thyroid cancers, which resulted in improved responses compared to standard chemotherapy. We present clinical examples of excellent responses in spinal metastatic disease which have not been specifically documented in the literature, as most clinical trials evaluate treatment response based on visceral disease. This review is useful for the spine surgeons treating patients with metastatic disease as knowledge of these responses could help with timing and planning of surgical interventions, as well as promote multidisciplinary discussions, allowing development of an individualized treatment strategy to patients presenting with widespread multifocal progressive disease, where surgery could lead to suboptimal results.

show abstract

Spine metastasis in patients with prostate cancer: Survival prognosis assessment

Cited by 7 publications

References 51 publications

Parathyroid hormone-related protein as a potential prostate cancer biomarker: Promoting prostate cancer progression through upregulation of c-Met expression

Parathyroid hormone-related protein as a potential prostate cancer biomarker: Promoting prostate cancer progression through upregulation of c-Met expression

Survival Rate after Palliative Surgery Alone for Symptomatic Spinal Metastases: A Prospective Cohort Study

Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy

Contact Info

Product

Resources

About